Official OCEMS site ↗
← Medication guides

Field medications · Adult & pediatric guidance · BLS / ALS

DuoDote (atropine / pralidoxime)

Combination auto-injector for organophosphate/nerve-agent toxicity, with age and weight restrictions.

OCEMS source summary · Updated 2026-09-16

Check before giving

  • For patients older than 65, B-035 requires weight of at least 80 kg to receive an auto-injector.
  • Do not exceed 3 devices unless definitive medical care is available. Ensure scene safety and move to a safe area when possible.

Use in OCEMS

  • For possible/known organophosphate insecticide or nerve-agent exposure with a compatible cholinergic syndrome.
  • B-035 uses salivation, tearing, urination, defecation, GI upset, emesis, and constricted pupils to describe the syndrome.

Adult / adolescent

Indication / routeDose & limits
Respiratory distress with cholinergic findings2 auto-injectors under the B-035 table.
Severe respiratory distress with agitation and cholinergic findings3 auto-injectors under the B-035 table.
No signs/symptomsMonitor for findings every 15 minutes; the table does not instruct prophylactic injection.

Pediatric

  • For patients younger than 12, B-035 requires a weight of at least 30 kg to receive an IM auto-injector.
  • For a smaller child, do not improvise a partial auto-injector dose; use the pediatric poisoning standing order and medical direction.

Pediatric dose by age / weight

  • B-035: weight determines eligibility in children younger than 12; clinical signs determine the number of complete devices. Do not divide an auto-injector.
Age / weightClinical findingsIM auto-injectors
Younger than 12 and below 30 kgAny findingsNot eligible under B-035; pediatric poisoning pathway/base direction
Younger than 12 and at least 30 kg, or age 12–14Respiratory distress with SLUDGEM2 devices
Younger than 12 and at least 30 kg, or age 12–14Severe respiratory distress, agitation, and SLUDGEM3 devices
Eligible child; no symptomsNo respiratory distress / SLUDGEMMonitor every 15 minutes; no prophylactic dose

Preparation & reassessment

  • Use the mid-anterolateral thigh. Remove the safety release, apply the injector at 90°, and hold for at least 10 seconds as specified by B-035.
  • Control/dispose of the exposed needle safely. Document product, time, and site; seek medical evaluation after the incident.